Building on dermatology’s recent success

Once cast off by most pharmas and investors, dermatology drug development is experiencing a renaissance. A standout commercial success has put atopic dermatitis on the map. Each new psoriasis therapy is extending efficacy. And emerging drug classes are promising to expand the pool of responders, both within dermatology’s major indications and into new ones.

The perception now is that dermatological diseases — specifically those that fall in the exceptionally hot area of inflammation and immunology (I&I) — offer some of the industry’s largest untapped markets, and that patient demand within those markets is high. ...